Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on SalesTimes Interest Earned

60 Degrees Pharmaceuticals (SXTP) Enterprise Value (2022 - 2025)

60 Degrees Pharmaceuticals (SXTP) has disclosed Enterprise Value for 4 consecutive years, with -$4.2 million as the latest value for Q3 2025.

  • On a quarterly basis, Enterprise Value rose 17.49% to -$4.2 million in Q3 2025 year-over-year; TTM through Sep 2025 was -$4.2 million, a 17.49% increase, with the full-year FY2024 number at -$3.5 million, down 56.62% from a year prior.
  • Enterprise Value was -$4.2 million for Q3 2025 at 60 Degrees Pharmaceuticals, down from -$2.0 million in the prior quarter.
  • In the past five years, Enterprise Value ranged from a high of -$29993.0 in Q1 2023 to a low of -$5.1 million in Q3 2024.
  • A 4-year average of -$2.1 million and a median of -$2.1 million in 2023 define the central range for Enterprise Value.
  • Peak YoY movement for Enterprise Value: increased 20.7% in 2023, then crashed 9799.72% in 2024.
  • 60 Degrees Pharmaceuticals' Enterprise Value stood at -$837185.0 in 2022, then plummeted by 164.52% to -$2.2 million in 2023, then tumbled by 56.62% to -$3.5 million in 2024, then dropped by 21.06% to -$4.2 million in 2025.
  • Per Business Quant, the three most recent readings for SXTP's Enterprise Value are -$4.2 million (Q3 2025), -$2.0 million (Q2 2025), and -$3.5 million (Q1 2025).